Rhythm Pharmaceuticals, Inc. RYTM
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -13.52%
- 1 year
- -17.21%
- Open
- 93.48
- Prev close
- 93.07
- Mkt cap
- 6.35B
- Vol
- 431.66K
- Avg vol
- 659.59K
- EPS
- -3.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 91.42
- High
- 95.60
- Forward P/E
- -147.03
- Beta
- 2.01
- Short ratio
- 13.64
- Inst. own
- 115.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 97.50
- 200-d avg
- 97.20
- 1y target
- 140.53
5D chart
Signals (130)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:30 AM | 1 day ago |
| RSI: Overbought | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:35 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:25 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:15 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:45 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
News
4 days ago zacks.com
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 week ago defenseworld.net
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.50 According to Brokerages
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twenty-two ratings firms that are covering the stock,…
1 week ago benzinga.com
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.37% on an annualized basis producing an average annual return of 51.51%. Currently, Rhythm Pharmaceuticals…
-
2 weeks ago benzinga.com
William Blair Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform rating.
-
2 weeks ago benzinga.com
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $146 to $145.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $130
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $105 to $130.
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $155 to $159.
-
3 weeks ago benzinga.com
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 38.46% on an annualized basis producing an average annual return of 50.82%. Currently, Rhythm Pharmaceuticals…
-
1 month ago benzinga.com
Rhythm Pharmaceuticals Receives Health Canada Approval Of IMCIVREE For Additional Indication Of Weight Management In Adult And Pediatric Patients 4 Years Of Age And Older With Acquired Hypothalamic Obesity
IMCIVREE was first approved by Health Canada in 2023 for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome (BBS), or genetically…
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.53% on an annualized basis producing an average annual return of 51.66%. Currently, Rhythm Pharmaceuticals…
2 months ago benzinga.com
Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.99% on an annualized basis producing an average annual return of 52.06%. Currently, Rhythm Pharmaceuticals…
-
2 months ago benzinga.com
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120
Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Hold rating and announces Price Target of $120.
-
2 months ago benzinga.com
Rhythm Pharmaceuticals Receives Marketing Authorization For IMCIVREE From Japan's Ministry Of Health To Treat Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today…
2 months ago benzinga.com
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Rhythm Pharma shares rise after U.K. expands Imcivree authorization for acquired hypothalamic obesity in adults and children 4 and older.
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.
-
2 months ago benzinga.com
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143
Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $142 to $143.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $141 to $155.
-
2 months ago benzinga.com
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $155 to $160.
2 months ago benzinga.com
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call
Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to…
-
2 months ago benzinga.com
Rhythm Pharmaceuticals Q2 EPS $(0.73) Beats $(0.82) Estimate, Sales $71.255M Beat $67.277M Estimate
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 2.67 percent increase over losses…
-
2 months ago benzinga.com
Rhythm Pharmaceuticals Announces Preliminary Results From Ongoing Phase 2 Trial Evaluating RM-718 In Patients With Acquired Hypothalamic Obesity; BMI Reductions Consistent With Setmelanotide And Bivamelagon; Sees -11.6% Mean Reduction In BMI From Baseline At Week
Eleven patients with acquired HO were enrolled in the ongoing, open-label trial. Key preliminary findings include:-11.6% reduction in mean BMI from baseline (n=7) after 16 weeks of RM-718;RM-718…
-
3 months ago benzinga.com
JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145
JP Morgan analyst Priyanka Grover initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight rating and announces Price Target of $145.
-
3 months ago benzinga.com
Rhythm Pharmaceuticals Announces That Results From Its Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide, A Melanocortin-4 Receptor Agonist, In Patients With Acquired Hypothalamic Obesity Have Been Published In The New England Journal Of Medicine
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced…
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $137 to $141.
-
4 months ago benzinga.com
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $151.
-
4 months ago benzinga.com
Rhythm Pharmaceuticals Presents Data From Multiple Presentations At Endocrine Society's Annual Meeting
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced…
4 months ago benzinga.com
Why Is Rhythm Pharma Stock Jumping Today?
Rhythm Pharma Phase 2 data showed improvements in BMI, body composition, hunger symptoms, and behavior in PWS patients.
-
4 months ago benzinga.com
Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $155
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $144 to $155.
-
4 months ago benzinga.com
Reported Saturday, Rhythm Pharmaceuticals Presents Phase 2 Data Showing Setmelanotide Achieves 3.06% Mean BMI Reduction And Clinically Meaningful Hyperphagia Improvements In Prader-Willi Syndrome Patients At ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in…
-
4 months ago benzinga.com
Rhythm Pharmaceuticals To Present Interim Phase 2 Setmelanotide Data In Prader-Willi Syndrome On June 13 At 9:00 a.m. ET
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced…
-
5 months ago benzinga.com
Rhythm Pharmaceuticals Announces Publication Of An Evidence-Based, Consensus-Driven Diagnostic Algorithm For Bardet-Biedl Syndrome
"Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria," was published in the peer-reviewed American Journal of Medical Genetics.This simplified and…
-
5 months ago benzinga.com
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $140 to $143.
5 months ago benzinga.com
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.
-
5 months ago benzinga.com
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $137
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $136 to $137.
-
5 months ago benzinga.com
Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $144
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $143 to $144.
5 months ago benzinga.com
Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call
Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call
-
6 months ago benzinga.com
Rhythm Pharmaceuticals Presents New Data At The Pediatric Endocrine Society Annual Meeting
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced…
-
6 months ago benzinga.com
Rhythmn Pharmaceuticals Announces European Commission Expansion Of The Marketing Authorization For Imcivree For Obesity And Control Of Hunger In Adults And Children 4 Years Of Age And Above With Acquired Hypothalamic Obesity
"This EC authorization is an important step toward making the first new treatment option available to people living with acquired HO in Europe," said David Meeker, M.D., Chairman, President and Chief…
-
7 months ago benzinga.com
Rhythm Pharma Says EMA CHMP Issues Positive Opinion To Expand IMCIVREE Use In Hypothalamic Obesity
-- European Commission decision anticipated in second quarter of 2026 --BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage…
-
7 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $105
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $100 to $105.
-
7 months ago benzinga.com
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $142
Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $131 to $142.
-
7 months ago benzinga.com
B of A Securities Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $149
B of A Securities analyst Tazeen Ahmad maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $139 to $149.
-
7 months ago benzinga.com
PANTHERx Rare Pharmacy Selected By Rhythm Pharma As Exclusive U.S. Pharmacy Distribution Partner For Expanded Indication Of IMCIVREE For Acquired Hypothalamic Obesity
PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Rhythm Pharmaceuticals,
7 months ago benzinga.com
Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy
FDA expands Rhythm Pharmaceuticals Imcivree approval for rare hypothalamic obesity, showing strong weight loss results.
-
7 months ago benzinga.com
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $152 to $155.
-
7 months ago benzinga.com
Reported Earlier, Rhythm Pharmaceuticals Secures FDA Approval Of IMCIVREE For Rare Acquired Hypothalamic Obesity, Marking First-Ever Approved Treatment For The Disease
First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or…
-
7 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $100
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $110 to $100.
7 months ago benzinga.com
Why Playboy Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Playboy (PLBY) shares rise in pre-market trading after reporting better-than-expected Q4 results. Other gainers include PTOR, LNAI, LIDR, ISPC, WNW, JVA, NUAI, XLO, and BW. Losers include PRSO, DFLI,…